Skip to navigation Skip to content

Hereditary transthyretin amyloidosis (HTA) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070419

Expand/Collapse all sectionsExpand all



HTA restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

A linked attachment is available for staff only (i.e. under IPS/FOI) PBS HTA restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Hereditary transthyretin amyloidosis - vutrisiran - initial authority application (PB367)

Hereditary transthyretin amyloidosis - vutrisiran - continuing authority application (PB368)

Services Australia website

Hereditary transthyretin amyloidosis

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item

Description

1

Is there an age restriction for patients applying for PBS-subsidised treatment of HTA?

Patients must be aged 18 years or older.

2

Are hospital details required for authority applications for vutrisiran?

Yes. Hospital details:

  • are required because vutrisiran is PBS-subsidised under Section 100 arrangements for Highly Specialised Drugs (HSD) Program
  • must be provided for each application for S100 HSD

3

Can increased quantity and/or repeats be authorised for vutrisiran?

No increases (NO INC) in the PBS-listed maximum quantity and repeats are allowed for this item.